Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $605.45M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 0.84M
Average 0.54M
Balance Sheet
Inspect the capital base behind the business.
Assets
$430.99M
FY 2025 · Annual
-24.3% YoYLiabilities
$29.54M
FY 2025 · Annual
-61.8% YoYEquity
$401.45M
FY 2025 · Annual
-18.4% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $323.5M |
| Short-term Investments | $216.3M |
| Other Current | $5.2M |
| Total Current Assets | $544.9M |
| PP&E (Net) | $1.8M |
| Other Non-current | $6.9M |
| Total Non-current Assets | $8.7M |
| Total Assets | $553.6M |
Analysis
Selected assets total $553.6M for Latest. The largest visible component is Cash & Equivalents at $323.5M, about 58.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 10, 2026 |
How much cash does BCAX have?
Bicara Therapeutics Inc. Common Stock (BCAX) reported $96.69M in cash and equivalents in fiscal 2025.
How much debt does BCAX carry?
Bicara Therapeutics Inc. Common Stock (BCAX) reported $1.71M of total debt, with net debt of -$94.97M.
Continue the stock analysis
Jump to another research area for this company.